.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Recent research identifies a critical pathway involving NINJ2 and Colitis Healing. Activation-induced cytidine deaminase (AID), usually associated with antibody diversity in B cells, also plays a pivotal role in the gut. Scientists found that AID is significantly expressed in colonic epithelial cells (CECs) during active inflammation. This discovery sheds light on how the body manages mucosal repair and inflammation in conditions like ulcerative colitis.
The study utilized a colorectal cancer cell line (DLD-1) to observe the effects of AID overexpression. Researchers identified over 600 genes induced by AID, including those within the mTOR and MAPK signaling pathways. Specifically, the expression of the NINJ2 gene increased fivefold. AID binds directly to the NINJ2 promoter and enhancer regions. Subsequently, it induces DNA demethylation, which triggers transcriptional upregulation. This molecular switch is essential for maintaining the integrity of the colonic lining.
Furthermore, the physiological impact of this pathway was tested in mouse models. AID-knockout mice showed a significant delay in recovery from induced colitis compared to wild-type mice. Because NINJ2 expression was lower in these knockout mice, the wound healing process stalled. Therefore, the researchers concluded that inflammation-driven AID upregulation is a protective response. It facilitates tissue repair by boosting NINJ2 transcription through epigenetic modifications. This process ultimately promotes faster resolution of intestinal damage.
NINJ2 is a cell surface adhesion protein. In the colon, it promotes tissue repair and wound healing after inflammatory injury by facilitating epithelial cell interactions.
AID binds to specific gene regions and promotes DNA demethylation. This epigenetic change allows genes like NINJ2 to be expressed more easily during periods of cellular stress or inflammation.
Understanding how the body naturally heals colonic wounds could lead to new therapies. Boosting the AID-NINJ2 pathway might accelerate recovery for patients suffering from inflammatory bowel disease.
Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A new study reveals that Activation-induced cytidine deaminase (AID) enhances the expression of the NINJ2 gene through DNA demethylation. This pathway is crucial for colonic wound healing and recovery from colitis, offering potential new avenues for treating inflammatory bowel disease and colorectal health.
4 months ago
Review how tailored exercise programs benefit frail older patients with heart failure. Explore pathophysiological mechanisms, individualized training prescriptions, and strategies to overcome adherence barriers in clinical practice.
Today
Leucine Rich Bio has introduced South Asia's first comprehensive vaginal microbiome test, BugSpeaks. By profiling microbial dysbiosis, pathogens, and antimicrobial resistance, this next-generation diagnostic platform provides clinicians with deeper insights into recurrent infections, fertility, and reproductive health.
Today
In high-risk pulmonary embolism complicated by severe anemia and active uterine bleeding, systemic thrombolysis is contraindicated. Large-bore aspiration thrombectomy provides rapid hemodynamic rescue without fibrinolysis, supported by inferior vena cava filter placement and multidisciplinary critical care.
Today
This comparative study evaluates posterior labral tears with and without glenohumeral instability, highlighting distinct demographic patterns, MRI underestimation in stable shoulders, and successful arthroscopic repair outcomes.
Today
A clinical study demonstrates that early intervention with tocilizumab, either as monotherapy or bridged with corticosteroids, achieves significant proptosis reduction and resolves active inflammation in treatment-naive thyroid eye disease.
Today
